Figure 2).

A Survival rate in weeks. Animals were monitored for 20 weeks immediately following the first cycle of doxorubicin (DOXO) administration (7.5 mg/kg). The vertical arrow indicates the second cycle of DOXO administration (12.5 mg/kg) to the high-dose group. No deaths occurred in the control group. One death occurred in the low-dose group shortly after drug administration. In contrast, several deaths occurred in the high-dose group after the additional dose of DOXO, indicating a dose-dependent pattern of mortality. B Weight measurement. The control group experienced gradual weight gain, while the low-dose group displayed a softened curve after the first four weeks. In addition to the initial weight loss beginning at four weeks, the high-dose group demonstrated intensified weight loss after the second DOXO cycle followed by subsequent weight gain that could be attributed to serositis (pleural and peritoneal effusions). The presence of serositis that had been detected in vivo during echocardiography of the high-dose animals was confirmed at the time of heart dissection.